Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms by Jurczak, Wojciech et al.
110
Review
Nuclear Medicine Review 2007
Vol. 10, No. 2, pp. 110–115
Copyright © 2007 Via Medica
ISSN 1506–9680
Wojciech Jurczak1, Alicja Hubalewska-Dydejczyk2,
Agnieszka Giza1, Anna Sowa-Staszczak2, Bohdan Huszno2,
Aleksander B. Skotnicki1
1Department of Haematology, Collegium Medicum, Jagiellonian
University, Kraków, Poland
2Nuclear Medicine Unit, Department of Endocrinology, Collegium
Medicum, Jagiellonian University, Kraków, Poland
[Received 4 IV 2007; Accepted 24 IV 2007]
Abstract
Ibritumomab, an 90Yttrium (90Y) labelled radioimmunoconjugate,
is registered in Europe to treat follicular lymphomas. Its mode
of action combines the selectivity of monoclonal antibodies with
the efficiency of radiotherapy, making it a unique and useful
therapeutic agent. This paper is for haemato-oncologists with a
decent practice in lymphoma therapy, who have not yet used
ibritumomab themselves. It summarizes clinical trials with ra-
dioimmunotherapy, indicating clinical situations where it may
be specifically useful.
Key words: radioimmunotherapy, ibritumomab, 90Y-ibritumomab
tiuxetan (Zevalin), lymphoma
Introduction
Monoclonal antibodies have changed the treatment and prog-
nosis of B cell Non Hodgkin Lymphoma (NHL). Until recently, it
was generally accepted that “aggressive” lymphomas are poten-
tially curable, while “indolent” lymphomas tend to have a progres-
sive course with multiple relapses. Chemotherapy is effective against
most dividing cells, but relatively inefficient against tumours with a
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low proliferation fraction. Classical radiotherapy has an established
role in treating localized disease; however, in advanced clinical stag-
es only total body irradiation (TBI), one of the transplant condition-
ing regimens, is applicable. Both monoclonal antibodies registered
in Europe for treatment of B cell lymphomas (Rituximab and ibritu-
momab tiuxetan) are capable of damaging non proliferating tumour
cells in patients with disseminated disease, enhancing the efficien-
cy of chemotherapy and improving its results. Rituximab is a ‘na-
ked’ monoclonal antibody exercising its action through comple-
ment mediated cytotoxicity (CMC), antibody dependent cellular
cytotoxicity (ADCC) and synergism with chemotherapy. Converse-
ly, immune mechanisms play a limited role in radiolabelled anti-
body (ibritumomab — tiuxetan), which is in fact a clever way to
deliver an isotope to the clusters of lymphoma cells. While most
haemato-oncologists know and widely use Rituximab, their experi-
ence with ibritumomab is rather limited. Radioimmunoconjugates
have a different mode of action than “naked” monoclonal antibod-
ies. Understanding their strength and limitations is essential in or-
der to treat lymphoma patients most efficiently.
Differences between radioimmunoconjugates
and “naked” monoclonal antibodies
Rituximab, an anti CD 20 monoclonal antibody, was a true rev-
olution in the treatment of B cell lymphomas, and chemoimmuno-
therapy became the 'golden standard' in diffuse large B cell lym-
phoma (DLBCL) [1] and follicular lymphoma (FL) [2]. Rituximab in
maintenance therapy [3] in FL has recently been registered in Eu-
rope and its final approval in chronic lymphocytic leukaemia (CLL)
is expected later this year. Chemoimmunotherapy improves the
outcome of other subtypes of B cell malignancies (i.e. mantle cell
lymphoma — MCL or marginal zone lymphoma — MZL); however,
they are not frequent enough to allow proper registration studies.
So, is there any possibility for further improvement? Mono-
clonal antibodies are relatively big molecules, poorly penetrating
grossly enlarged, partly fibrosed lymph nodes (Table 1). Hundreds
of Rituximab particles have to be bound to the cellular surface to
damage it. It works very well in “liquid tissues”, like bone marrow
(BM) or peripheral blood (PB), in which the cells are easily acces-
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sible. A single ibritumomab-tiuxetan molecule with thousands of
90Y atoms attached is capable of killing several adjacent cells (Fig-
ure 1). The average range of Beta particles emitted by 90Y is about
5 mm, so it is effective in lymph nodes and tissue lymphoma infil-
trates even if ibritumomab does not reach every cell. Its action is
less selective than Rituximab: what is desired in lymph nodes is a
disadvantage in bone marrow and haematological toxicity is a
dose limiting factor [4]. Radioimmunotherapy (RIT) is contraindi-
cated in patients with a significant bone marrow lymphoma infil-
tration (> 25%), BM hypoplasia or peripheral cytopenia (leuko-
cytes < 1000/ul, blood platelets < 100,000/ul).
Haematological toxicity of RIT is due to stem cell damage.
The period of cytopenia is postponed by 3-5 weeks and pro-
longed compared to what would have been expected after che-
motherapy. Cytostatics either cause an immediate drop in the
blood counts (if BM infiltration is important) or a gradual one, 7–
10 days later, due to damage of the progenitor cells in the bone
marrow (which under normal circumstances would proliferate and
become mature cells at that time). Late onset cytopenia after
RIT is caused by the direct damage of the early stem cells, usu-
ally quiescent, and consequently indestructible by standard dose
chemotherapy. Its severity depends on lymphoma subtype, bone
marrow involvement and preceding chemotherapy. Stem cell
involvement is confirmed by clonogenic capacity studies [5].
Therefore, retreatment with ibritumomab, although possible,
should be used with caution.
Rituximab is part of an established standard, and we have a
lot of experience with its application. Ibritumomab is registered in
Europe for Rituximab relapsing or refractory FL, and it is the only
therapy approved for use after Rituximab failure.
The differences between radioimmunotherapy
and classical radiotherapy
Conventional involved field radiotherapy (IFRT) plays an impor-
tant role in lymphoma treatment as a consolidative approach in
localized diseases. An absorbed dose of 30–40 Gy delivered in
20–30 daily fractions is usually sufficient to deal with moderately
enlarged lymph nodes within the irradiated areas. Poor vasculari-
sation or heavy fibrosis of the tumour does not impair IFRT effec-
tiveness. Extended field radiotherapy, like mantle field RT, has a
limited capacity to deal with advanced disease and is generally
abandoned because of the late side effects (increased risk of sec-
ondary solid tumours and cardiovascular accidents). Irradiating the
whole body at the same time increases the efficiency but is possi-
ble only as an element of transplant conditioning procedure. Total
body irradiation (TBI) is used in high-risk cases, when the efficiency
counts more than late side effects. In TBI procedure 10–12 Gy de-
livered in 6 fractions, every 12 hours have a similar biological effect
to 30 Gy IFRT (where the dose per fraction is smaller, and the long-
er time interval allows for cellular repair processes). In external beam
radiotherapy, apart from some heart and lung shielding, the ab-
sorbed dose is equal in all irradiated areas.
Table 1. Comparison between rituximab and ibritumomab tiuxetan
Rituximab — “naked” MoAb Ibritumomab tiuxetan
— radioimmunoconjugate (90Y)
Phase of drug development Well established, based on several The ideal place and dose schedules to be established
IIIrd phase clinical trials
Dose 375 mg/ m2, 4–8 doses, usually ~ 1 mg/m2, usually as a single dose, either in
with concomitant chemotherapy monotherapy or as a consolidation strategy
or later as a maintenance
Mechanism of cellular damage Complement mediated, ADCC, Radiotherapy
direct damage/apoptosis,
synergism with chemotherapy
Haematological toxicity Literally none Dose limiting
Registration FL & DLBCL chemoimmunotherapy, Rituximab relapsing or refractory FL or transformed FL,
maintenance of FL the only approved therapy for use after Rituximab failure
Most effective In “liquid tissue”: bone marrow and blood In moderately enlarged LN, even when enlarged,
partly fibrosed
Limitations Large, fibrosed, poorly vascularised LN Extensive BM (> 25%) or blood involvement
Why it should be used Proven EFS and OS benefit Best palliation method in low-grade lymphoma
a standard element of first line patients failing several previous treatment lines
therapy of DLBCL/ FL/ MCL If used early in the course of the disease, may prevent
further relapses in FL, resulting in a survival plateau
MoAb — monoclonal antibodies; ADCC — antibody dependent cell mediated cytotoxicity; DLBCL — diffuse large cell lymphoma; EFS — event free survival; OS — overall survival;
MCL — mantle cell lymphoma; BM — bone narrow; LN — lymph nodes
Figure 1. Comparison of the doses and mode of action of monoclonal
antibodies: several particles of a “naked” antibody (Rituximab) are nec-
essary to kill a single lymphoma cell, while one particle of radioimmuno-
conjugate (Ibritumomab tiuxetan) is potentially capable of killing several
adjacent cells.
Rituximab Ibritumomab
~ 1 mg/m2375 mg/m2
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In RIT, radiolabelled monoclonal antibodies are administered
intravenously. Ibritumomab is directed against a CD20 (cluster
differentiation) molecule, present on most B lymphocytes. Its infu-
sion is preceded by two doses of Rituximab (on day –7 and 0) to
saturate all CD20 antigens on circulating B lymphocytes. After
a short distribution phase, most radiolabelled antibodies are bound
to the tumour. RIT is therefore a “total tumour radiotherapy”, in
which the absorbed dose is greater in the lymphoma and smaller
in the tissue which is not infiltrated (Figure 2).
Both radioimmunotherapy and conventional external beam ir-
radiation use radiation to destroy malignant cells. The effects of
irradiation depend on the distribution and number of ionizations
in a cell (which is related to the dose) and biological factors such
as the phase of the cell cycle, degree of hydration or oxygenation.
The cells are damaged either as a result of several “direct hits” of
important structures (i.e. DNA, proteins) or due to the devastating
effect of free radicals ∞OH, e–aq, ∞H and H3O formed during water
radiolysis. In RIT, the low dose rate of the radiation delivered con-
stantly exerts a greater anti-tumour activity than an equivalent dose
of conventional external beam radiation, in which the cells are able
to repair the damage between subsequent fractions. Paradoxi-
cally, radioimmunotherapy may work better for tumours which we
can measure in millimetres or centimetres than for micrometastas-
es or single cells, as with fewer antibodies attached, the cross-fire
effect is less prominent. On the other hand, we should be realistic
about the ability of ibritumomab to deal with a very large tumour
burden; most of the patients with enlarged lymph nodes exceed-
ing 5–7 cm will have only a partial response.
Radioimmunotherapy in follicular lymphoma
Four registration clinical trials with RIT were performed in heavily
pretreated low-grade lymphoma patients having failing several pre-
vious treatment lines. Two of them were in fact dose escalation
studies, setting 14.8 MBq/kg (not exceeding 1200 MBq/patient)
as a standard for patients without cytopenia [6] and 11.1 MBq/kg
for those with mild thrombocytopenia [7]. The randomized com-
parison with Rituximab (n = 147) [8] and the trial in which ibritu-
momab was given to Rituximab refractory cases (defined as no
response or progression in less than six months) [9] demonstrat-
ed a higher response rate after radioimmunotherapy. In four trials
analyzed together (n = 211), there were 73–83% of responders
who achieved 29–47% of complete regression of the disease or
complete regression unconfirmed (CR/CRu). The average pro-
gression free survival (PFS) was nine months, and the projected
five year overall survival (OS) was 53%. All patients with partial
responses eventually progressed. PFS duration increased with
the quality of response: from 12 months in responding patients to
23 months in CR/CRu cases. There were two papers published
on the long time follow-up of these studies, identifying 37% (78/
/211 patients) with continuous remission at 12 months [10, 11].
A third of these patients had been treated with at least three pre-
vious therapies, and 37% of them had not responded to their last
therapy. Median time to progression was 29 months and project-
ed five year OS was 81%. Ibritumomab has an established role as
the best possible palliation, effective also in cases refractory to
previous treatments. Most responses are durable — longer than
the time to progression after the preceding therapy. There is even
a small subgroup of “long time survivors” with a plateau on the
Kaplan Meier curve (about 20% of all patients, nearly 40% of those
who were in constant CR after the first 12 months). Similar results
were confirmed in 250 relapsing/refractory low grade lymphoma
patients treated with tositumomab, an anti CD20 131Iodine labelled
radioimmunoconjugate [12]. The integrated analysis of five clini-
cal trials revealed a 47–68% response rate with 20–38% CR and
17% 5-year PFS. Similarly to ibritumomab, 32% (81/250 patients)
who were in an on-going remission at 12 months had an excellent
prognosis with median PFS of 45 months (Table 2, 3).
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A complete response is the single most important condition
for long time to progression (TTP). In one of the studies [13] dura-
ble responses were observed in 75% of patients with CR con-
firmed by a masked independent randomized radiology and on-
cology review (MIRROR) panel. We can increase the CR rate after
radioimmunotherapy by: 1) applying it earlier, before the failure of
several previous treatment lines, 2) using it as a consolidation
strategy after the initial cytoreduction or 3) escalating its dose or
retreating patients with partial regression (PR).
Several studies and comparisons [14] demonstrate the in-
creased effectiveness of radioimmunotherapy if used earlier in the
course of a disease (Figure 3). The CR/CRu rate is higher (51%
vs. 21%, p < 0.01) and the time to progression increases (15.4
vs. 9.2 months, p < 0.05) in patients treated at first relapse com-
pared with those who received two or more prior therapies [15].
First line ibritumomab with further Rituximab maintenance in ad-
vanced stage FL at diagnosis was explored by Sweetenham et al.
[100% response rate (RR), 60% CR, n = 10] [16]. A larger study
(n = 76) with a longer follow-up was done with tositumomab [17]:
RR and CR rates were 95% and 75% respectively; 59% of patients
were in a continuous CR at five years with projected medium pro-
gression free survival of 6.1 years.
Results were even more encouraging when ibritumomab was
used to consolidate an initial response after abbreviated cyclo-
phosphamide, doxorubicin, vincristine, prednisolone-rituximab
(CHOP-R) [18] or fludarabine, mitoxantrone (FM) [19] chemo-
therapy. To investigate this matter further, a phase III study was
completed, in which 360 patients with a CR/PR after initial cyclo-
phosphamide, vincristine, prednisolone (CVP) or cyclophospha-
mide, doxorubicin, vincristine, prednisolone (CHOP) chemothera-
py were randomized to RIT or observation [20]. The final analy-
sis is expected this year during the American Society of Hema-
tology (ASH) meeting.
Hematologic toxicity is a dose-limiting factor. Radioimmuno-
therapy is not offered more than twice to the same patient. Esca-
lating the dose requires a stem cell support (transplant condition-
Table 2. Radioimmunotherapy as best palliation method in heavily pretreated, low-grade lymphoma patients (summary of nine clinical trials
with nearly 500 patients included)
Ibritumomab tiuxetan (90Y) Tositumomab (131I)
Number of patients 211 patients included in 4 registration trials 250 patients included in 5 clinical trials
Responders 73–83% (medium PFS–12 months) 47–68% (medium PFS–12.9 months)
CR/CRu 29–47% (medium PFS–23 months) 20–38% (medium PFS–28 months)
At 5 years 53% OS, about 15% PFS 17% PFS
CR/CRu — complete remission or completed remission unconfirmed; PFS — progression free survival; OS — overall survival
Table 3. Long-lasting PFS in heavily pretreated, low-grade lymphoma patients after radioimmunotherapy
Ibritumomab tiuxetan (90Y) Tositumomab (131I)
Number of patients 78/211 — 37% of patients included 81/250 — 32% of patients included in 5 clinical trials
in 4 registration trials
Group description 33% — after failing > 3 regimens 33% — after failing > 4 regimens
37% — refractory to previous therapy 37% — refractory to previous therapy
Medium PFS 28 months 46 months
At 5 years 81% OS, about 25% PFS About 40% PFS
PFS — progression free survival; OS — overall survival
ing regimens, sometimes applied in transformed follicular lym-
phoma, are described further in the DLBCL section).
German Group has recently published an FL therapy algo-
rithm including RIT [21]. Ibritumomab is recommended as the first
line treatment in patients not eligible to chemotherapy and at the
first relapse in low risk elderly patients. In first relapse of young
patients or high-risk elderly patients, radioimmunotherapy is one
of the options following initial chemoimmunotherapy.
Radioimmunotherapy in mantle cell
lymphoma (MCL)
The first results of RIT in relapsed patients with a high tumour
burden were discouraging, with an average PFS of 3–5 months [22,
23]. Although cytoreduction with chemoimmunotherapy improves
Figure 3. Response rate to radioimmunotherapy in subsequent treatment
lines [9, 10, 14, 16]. RR — response rate; CR — complete regression.
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the response rate (RR) and prolongs PFS to 7.5 months [24], ibritu-
momab is not spectacularly effective in relapsed MCL patients. There
are currently two clinical trials with RIT used as a consolidation of
first line chemoimmunotherapy in patients unsuitable for dose es-
calation or stem cell transplants: The Eastern Cooperative Oncolo-
gy Group (ECOG) study with 4 cycles of cyclophosphamide, doxo-
rubicin, vincristine, prednisolone-rituximab (CHOP-R) regimen [25]
and a Polish Lymphoma Research Group (PLRG) study with 3–6
cycles of fludarabine, cyclophosphamide mitoxantrone-rituximab
(FCM-R) [26]. The preliminary results suggest a very good response
rate (84–100%) with a high proportion of CR (45–85%). Progression
free survival rates (PFS) are yet to be determined, but the median
was not reached after two years of follow-up. If it is confirmed by
longer follow-up, radioimmunotherapy consolidation may become
a standard consolidation in elderly MCL patients.
Radioimmunotherapy in diffuse large
cell lymphomas (DLBCL)
In DLBCL and transformed FL, ibritumomab monotherapy
shows only moderate activity in patients treated earlier with chemoim-
munotherapy (20% RR, 4% CR) [27]. At present it is used as
a consolidation strategy. In elderly patients it may improve the first
line therapy efficacy and reduce its side effects; shortening chemoim-
munotherapy reduces the risk of cardiac toxicity risk due to anthra-
cyclines. This approach was initially investigated by Hamlin [28]
and Morchauser [29] in first line and relapsed patients, respective-
ly. A randomized comparison which will eventually determine the
RIT role of ibritumomab as a consolidation therapy in Aggressive
Lymphoma (ZEAL study) in first CR/CRu is currently ongoing.
Dose escalation and stem cell transplants is the treatment of
choice in relapsed DLBCL patients and at diagnosis high risk cases
at. Ibritumomab may be used as a transplant conditioning regi-
men in three possible ways:
— instead of TBI, by escalating RIT dose [30];
— combining a standard ibritumomab dose with a carmustine,
cytarabine, etoposide, melphalan (BEAM) or cyclophospha-
mide, carmustine, vinblastine (CBV) chemotherapy [31];
— using both escalating RIT dose and chemotherapy condition-
ing [32]. Combined conditioning strategies may enhance an
anti-lymphoma effect. Although an escalated dose of radio-
immunotherapy requires individual dosimetry, it is feasible for
elderly patients and allows autologous transplants to be per-
formed as outpatient procedures.
Summary
It is not yet proven that low grade lymphomas may be cured
with radioimmunotherapy. Ibritumomab is, however, the best pos-
sible palliation in cases relapsing or refractory to several previous
chemotherapy lines. Most patients respond, and some of them
are a true “long responders” with an evident plateau on survival
curves. The proportion of long progression free survivals increas-
es when radioimmunotherapy is applied earlier in the disease
course, optimally in the first relapse. Initial cytoreduction is always
worth considering in patients with a very large tumour burden,
although possibly is not necessary for those with lymph nodes
< 5–7 cm in diameter. The role of upfront radioimmunotherapy
(i.e. as a consolidation of first line treatment) has to be confirmed
in the phase III trials. Most clinical studies were performed in FL
patients, although radioimmunotherapy maybe equally efficient in
other B-cell low-grade lymphomas.
In aggressive lymphomas, RIT can be used as a consolida-
tion strategy: either as an element of transplant conditioning reg-
imen (in high-risk cases) or in monotherapy (in elderly patients).
Haematological toxicity is the only important side effect of ibri-
tumomab, and the quality of life is superior compared to chemo-
therapy. In pharmacy-economic analysis, RIT is fully justified when
compared to other monoclonal antibodies.
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